Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use

Chest

Volumn 145, Issue 4, 2014, Pages 695-703

  Petersen, Hans ^a   Sood, Akshay ^b   Meek, Paula M ^c   Shen, Xian ^b   Cheng, Yan ^b   Belinsky, Steven A ^a   Owen, Caroline A ^d   Washko, George ^d   Pinto Plata, Victor ^d   Kelly, Emer ^d   Celli, Bartolome ^d   Tesfaigzi, Yohannes ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERGLYCEMIC AGENT; INSULIN;

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG ACTIVITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SMOKING; SPIROMETRY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 84898734234     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0799     Document Type: Article

References (42)

1. American Lung Association. Trends in COPD (chronic bronchitis and emphysema): morbidity and mortality. American Lung Association website. http://www.lung.org/finding-cures/our-research/trend-reports/copd-trend-report. pdf. Published March 2013. Accessed September 25, 2013 .
2. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000; 118 (3): 656-664 .
3. Stavem K, Aaser E, Sandvik L, et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J. 2005; 25 (4): 618-625 .
4. Bang KM, Gergen PJ, Kramer R, Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993; 103 (2): 536-540 .
5. Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham study. Am Heart J. 1983; 105 (2): 311-315 .
6. Lange P, Nyboe J, Jensen G, Schnohr P, Appleyard M. Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur Respir J. 1991; 4 (9): 1080-1087 .
7. Cook NR, Hebert PR, Satterfield S, Taylor JO, Buring JE, Hennekens CH. Height, lung function, and mortality from cardiovascular disease among the elderly. Am J Epidemiol. 1994; 139 (11): 1066-1076 .
8. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996; 313 (7059): 711-715 .
9. Van den Eeden SK, Friedman GD. Forced expiratory volume (1 second) and lung cancer incidence and mortality. Epidemiology. 1992; 3 (3): 253-257 .
10. Rabe KF, Hurd S, Anzueto A, et al Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176 (6): 532-555 .
11. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ. 1977; 1 (6077): 1645-1648 .
12. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7 : 95-99 .
13. Casanova C, de Torres JP, Aguirre-Jaíme A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011 ; 184 (9): 1015-1021 .
14. Vestbo J, Edwards LD, Scanlon PD, et al ; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011 ; 365 (13): 1184-1192 .
15. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 ; 359 (15): 1543-1554 .
16. Nishimura M, Makita H, Nagai K, et al ; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 ; 185 (1): 44-52 .
17. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet. 2011; 378(9795): 991- 996.
18. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med. 2009 ; 361 (27): 2599-2608 .
19. Sood A, Petersen H, Blanchette C, et al. Wood smoke-associated chronic obstructive pulmonary disease (COPD) 2 underappreciated in the United States? [abstract] Am J Respir Crit Care Med. 2009 ; 179 (meeting abstracts): A4742 .
20. Sood A, Stidley CA, Picchi MA, et al. Difference in airflow obstruction between Hispanic and non-Hispanic White female smokers. COPD. 2008; 5 (5): 274-281 .
21. Bruse S, Sood A, Petersen H, et al. New Mexican Hispanic smokers have lower odds of chronic obstructive pulmonary disease and less decline in lung function than non-Hispanic whites. Am J Respir Crit Care Med. 2011; 184(11): 1254- 1260.
22. Akinbami LJ, Liu X. Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998-2009. NCHS Data Brief. 2011 ;(63): 1-8 .
23. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 ; 162 (6): 2152-2158 .
24. Kohansal R, Soriano JB, Agusti A. Investigating the natural history of lung function: facts, pitfalls, and opportunities. Chest. 2009; 135 (5): 1330-1341 .
25. Agusti A, Calverley PM, Celli B, et al ; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010 ; 11 : 122 .
26. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med. 1991; 85 (suppl B): 25-31 .
27. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis. 1978; 118(6 pt 2): 1- 120.
28. American Thoracic Society. Standardization of Spirometry, 1994 update. Am J Respir Crit Care Med. 1995; 152 (3): 1107-1136 .
29. Sood A, Petersen H, Blanchette CM, et al. Methylated genes in sputum among older smokers with asthma. Chest. 2012 ; 142 (2): 425-431 .
30. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease website. www.goldcopd.com. Updated 2008. Accessed September 25, 2013.
31. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002; 166 (5): 675-679 .
32. Celli B, Vestbo J, Jenkins CR, et al ; Investigators of the TORCH Study. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med. 2011 ; 183 (3): 317-322 .
33. Packard KA, Wurdeman RL, Arouni AJ. ACE inhibitorinduced bronchial reactivity in patients with respiratory dysfunction. Ann Pharmacother. 2002; 36 (6): 1058-1067 .
34. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Reninangiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond). 2012; 123 (8): 487-498 .
35. Yamazato Y, Ferreira AJ, Hong KH, et al. Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension. 2009 ; 54 (2): 365-371 .
36. Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012; 186 (1): 11-16 .
37. Podowski M, Calvi C, Metzger S, et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012 ; 122 (1): 229-240 .
38. Peinado VI, Pizarro S, Barberà JA. Pulmonary vascular involvement in COPD. Chest. 2008; 134 (4): 808-814 .
39. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986; 89 (3): 370-373 .
40. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, GA : United States Department of Health and Human Services, Centers for Disease Control and Prevention; 2006 .
41. van der Lende R, Kok TJ, Reig RP, Quanjer PH, Schouten JP, Orie NG. Decreases in VC and FEV1 with time: indicators for effects of smoking and air pollution. Bull Eur Physiopathol Respir. 1981; 17 (5): 775-792 .
42. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180(10): 948- 955.